UT Southwest Medical Center
Welcome,         Profile    Billing    Logout  
 23 Trials 
41 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morris, David
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
NCT05903131: A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Recruiting
2
96
US
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Washington University School of Medicine, National Cancer Institute (NCI)
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
10/28
10/29
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Recruiting
2
96
US
Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program
Washington University School of Medicine, Novo Nordisk A/S
Endometrial Hyperplasia
04/30
04/32
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Terminated
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/24
11/24
NCT05497934: The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear

Withdrawn
1
50
NA
Glycerol, Glycerin(e)
Nova Scotia Health Authority, Dalhousie University
Tympanosclerosis, Thickened Ears, Healthy, Surgery
10/23
03/24
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05492513: Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment

Recruiting
N/A
12
US
Grade 1 CI Therapy +Sensory Components
University of Alabama at Birmingham
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
11/25
03/26
NCT05515237: Constraint-Induced Movement Therapy Plus Sensory Components After Stroke

Recruiting
N/A
15
US
Grade 2-5 CI Therapy + Sensory Components
University of Alabama at Birmingham
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
03/26
06/26
NCT06310278: Ossiview Normative Mobility Data Collection Protocol

Recruiting
N/A
120
Canada
Ossicular mobility measurement
Audioptics Medical Incorporated
Conductive Hearing Loss, Middle Ear
10/24
10/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
NCT06930781: Evaluation of Clinical Outcomes of Ponto Procedures Performed in Settings Outside the Main Operating Room (i.e. Out-of-OR)

Not yet recruiting
N/A
270
NA
Ponto implantation
Oticon Medical
Hearing Loss, Bone Anchored Hearing Aids
10/26
12/26
Shore, Neal D
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study

Recruiting
3
100
Europe, US, RoW
padeliporfin VTP, WST11
Steba Biotech S.A., PrimeVigilance, ICON plc
Transitional Cell Cancer of Renal Pelvis and Ureter
06/25
01/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
NCT06636682: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Recruiting
2
100
US
FK-PC101, Standard of Care (SOC)
Cellvax Therapeutics Inc
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
02/27
05/27
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1
24
US
ZH9
Prokarium Ltd
NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
06/25
07/27
FORAGER-1, NCT05614739: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
535
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, enfortumab vedotin
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/27
06/27
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

Completed
N/A
804
Europe, Canada, US
Micro-US Targeted Biopsy, MRI Targeted Biopsy
Sunnybrook Health Sciences Centre, Exact Imaging
Prostate Cancer
09/24
11/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

Active, not recruiting
N/A
554
Canada, US
Cxbladder
Pacific Edge Limited
Hematuria, Urothelial Carcinoma
12/24
12/24
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morris, David
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
NCT05903131: A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Recruiting
2
96
US
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Washington University School of Medicine, National Cancer Institute (NCI)
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
10/28
10/29
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Recruiting
2
96
US
Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program
Washington University School of Medicine, Novo Nordisk A/S
Endometrial Hyperplasia
04/30
04/32
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Terminated
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/24
11/24
NCT05497934: The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear

Withdrawn
1
50
NA
Glycerol, Glycerin(e)
Nova Scotia Health Authority, Dalhousie University
Tympanosclerosis, Thickened Ears, Healthy, Surgery
10/23
03/24
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05492513: Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment

Recruiting
N/A
12
US
Grade 1 CI Therapy +Sensory Components
University of Alabama at Birmingham
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
11/25
03/26
NCT05515237: Constraint-Induced Movement Therapy Plus Sensory Components After Stroke

Recruiting
N/A
15
US
Grade 2-5 CI Therapy + Sensory Components
University of Alabama at Birmingham
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
03/26
06/26
NCT06310278: Ossiview Normative Mobility Data Collection Protocol

Recruiting
N/A
120
Canada
Ossicular mobility measurement
Audioptics Medical Incorporated
Conductive Hearing Loss, Middle Ear
10/24
10/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
NCT06930781: Evaluation of Clinical Outcomes of Ponto Procedures Performed in Settings Outside the Main Operating Room (i.e. Out-of-OR)

Not yet recruiting
N/A
270
NA
Ponto implantation
Oticon Medical
Hearing Loss, Bone Anchored Hearing Aids
10/26
12/26
Shore, Neal D
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study

Recruiting
3
100
Europe, US, RoW
padeliporfin VTP, WST11
Steba Biotech S.A., PrimeVigilance, ICON plc
Transitional Cell Cancer of Renal Pelvis and Ureter
06/25
01/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
NCT06636682: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Recruiting
2
100
US
FK-PC101, Standard of Care (SOC)
Cellvax Therapeutics Inc
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
02/27
05/27
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1
24
US
ZH9
Prokarium Ltd
NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
06/25
07/27
FORAGER-1, NCT05614739: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
535
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, enfortumab vedotin
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/27
06/27
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

Completed
N/A
804
Europe, Canada, US
Micro-US Targeted Biopsy, MRI Targeted Biopsy
Sunnybrook Health Sciences Centre, Exact Imaging
Prostate Cancer
09/24
11/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

Active, not recruiting
N/A
554
Canada, US
Cxbladder
Pacific Edge Limited
Hematuria, Urothelial Carcinoma
12/24
12/24
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29

Download Options